Leveraging synthetic gut microbiomes to understand the host and microbial determinants that promote dysbiosis
利用合成肠道微生物组来了解促进菌群失调的宿主和微生物决定因素
基本信息
- 批准号:RGPIN-2022-05301
- 负责人:
- 金额:$ 2.91万
- 依托单位:
- 依托单位国家:加拿大
- 项目类别:Discovery Grants Program - Individual
- 财政年份:2022
- 资助国家:加拿大
- 起止时间:2022-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The human gastrointestinal tract represents one of the most dense microbial ecosystems and, although likely underestimated. By providing unique enzymes and biochemical pathways, the gut microbiota regulates multiple aspects of host physiology, including metabolism, development and function of the immune and nervous system, as well as resistance to infection by pathogens. Adverse alterations of the structure and metabolic capacity of the microbiota, often referred to as dysbiosis, have been linked to numerous diseases, including inflammatory bowel disease (IBD), cancer, autoimmune diseases and metabolic disorders. However, defining what dysbiosis means on a compositional and functional level has proven to be difficult since disease-specific taxonomic signatures are not always consistently detected across multiple cohorts. Indeed, given the complexity of inter-microbe and microbe-host interaction networks within the gut ecosystem, it is difficult to decipher the physiological roles of individual members in natural communities. This is further complicated by the fact that multiple taxa possess similar metabolic capacities and are thereby functionally redundant. On the other hand, technical and practical constraints in culturing a proportion of gut bacteria have hindered the functional characterization of not-yet culturable or unknown taxa, which could play an important biological role in the complex microbial community. In addition, experimental animal studies of microbe-host crosstalk have shown limited reproducibility because of the inherent variability of the gut microbiota that can cause phenotypic variations. For these reasons, there is an emerging interest in developing standardized microbiota communities of reduced and known complexity, generally referred to as synthetic or defined microbial communities. In this project, we plan to leverage the use of synthetic microbiomes in order to delineate how the gut environment impacts the microbial ecosystem as well as how microbial factors from a perturbed community impact the host. Synthetic microbiomes representing human- or mouse-derived communities, either in conditions of health or disease, will be constructed in chemostat bioreactors where host-simulated environments encourage the stable growth of these communities. These communities will then be gavaged into germ-free mice, which provide the means to test the effectiveness of how well the bioreactors reflect composition and function of a given microbial community once within the gut environment as well as to determine what host factors impact the microbial ecosystem and which microbial factors contribute to host outcomes in a controlled and tractable system.
人类胃肠道是最密集的微生物生态系统之一,虽然可能被低估了。肠道微生物区系通过提供独特的酶和生化途径,调节宿主生理的多个方面,包括免疫和神经系统的新陈代谢、发育和功能,以及对病原体感染的抵抗力。微生物区系结构和代谢能力的不利变化,通常被称为生物失调,与许多疾病有关,包括炎症性肠病(IBD)、癌症、自身免疫性疾病和代谢紊乱。然而,在成分和功能水平上定义生物失调意味着什么已经被证明是困难的,因为在多个队列中并不总是一致地检测到特定于疾病的分类特征。事实上,鉴于肠道生态系统中微生物间和微生物-宿主相互作用网络的复杂性,很难破译自然群落中单个成员的生理作用。多个分类群具有相似的代谢能力,因此在功能上是多余的,这一事实使情况变得更加复杂。另一方面,培养一定比例的肠道细菌的技术和实践限制阻碍了尚未培养或未知的类群的功能表征,这些类群可能在复杂的微生物群落中发挥重要的生物学作用。此外,对微生物-宿主串扰的实验动物研究表明,由于肠道微生物区系的固有变异性,可能导致表型差异,因此重复性有限。由于这些原因,人们对开发降低和已知复杂性的标准化微生物群落产生了兴趣,这些群落通常被称为合成或定义的微生物群落。在这个项目中,我们计划利用合成微生物群的使用来描绘肠道环境如何影响微生物生态系统,以及来自扰动群落的微生物因素如何影响宿主。无论是在健康条件下还是在疾病条件下,代表人或鼠来源社区的合成微生物群将在恒化器生物反应器中构建,在那里宿主模拟环境鼓励这些社区的稳定增长。然后,这些群落将被灌胃到无菌小鼠中,这提供了一种手段,以测试生物反应器在肠道环境中反映给定微生物群落的组成和功能的有效性,并确定在受控和可驯化的系统中,哪些宿主因素影响微生物生态系统,哪些微生物因素对宿主结果做出贡献。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Philpott, Dana其他文献
Philpott, Dana的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Philpott, Dana', 18)}}的其他基金
Design of probiotic bacteria to promote digestive and metabolic health
益生菌的设计促进消化和代谢健康
- 批准号:
549693-2020 - 财政年份:2021
- 资助金额:
$ 2.91万 - 项目类别:
Collaborative Health Research Projects
Ecology of the intestinal microbe, Faecalibacterium prausnitzii
肠道微生物,普氏粪杆菌的生态学
- 批准号:
RGPIN-2016-06357 - 财政年份:2021
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
Design of probiotic bacteria to promote digestive and metabolic health
益生菌的设计促进消化和代谢健康
- 批准号:
549693-2020 - 财政年份:2020
- 资助金额:
$ 2.91万 - 项目类别:
Collaborative Health Research Projects
Ecology of the intestinal microbe, Faecalibacterium prausnitzii
肠道微生物,普氏粪杆菌的生态学
- 批准号:
RGPIN-2016-06357 - 财政年份:2020
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
Ecology of the intestinal microbe, Faecalibacterium prausnitzii
肠道微生物,普氏粪杆菌的生态学
- 批准号:
RGPIN-2016-06357 - 财政年份:2019
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
Ecology of the intestinal microbe, Faecalibacterium prausnitzii
肠道微生物,普氏粪杆菌的生态学
- 批准号:
RGPIN-2016-06357 - 财政年份:2018
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
Ecology of the intestinal microbe, Faecalibacterium prausnitzii
肠道微生物,普氏粪杆菌的生态学
- 批准号:
RGPIN-2016-06357 - 财政年份:2017
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
Ecology of the intestinal microbe, Faecalibacterium prausnitzii
肠道微生物,普氏粪杆菌的生态学
- 批准号:
RGPIN-2016-06357 - 财政年份:2016
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
Modeling host-microbe interactions in the intestinal ecosystem
肠道生态系统中宿主-微生物相互作用的建模
- 批准号:
RGPIN-2015-04063 - 财政年份:2015
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
Host-microbe interactions in the intestinal ecosystem regulated through Nod proteins
通过 Nod 蛋白调节肠道生态系统中宿主与微生物的相互作用
- 批准号:
RGPIN-2014-03896 - 财政年份:2014
- 资助金额:
$ 2.91万 - 项目类别:
Discovery Grants Program - Individual
相似国自然基金
近空间飞行器载MIMO SAR高分辨率、宽测绘带遥感成像机理与方法
- 批准号:41101317
- 批准年份:2011
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
基于大机动运动平台的特定目标多极化成像与匹配技术研究
- 批准号:11176022
- 批准年份:2011
- 资助金额:46.0 万元
- 项目类别:联合基金项目
相似海外基金
Orthogonal split luciferases for imaging multiplexed cellular behaviors
用于多重细胞行为成像的正交分裂荧光素酶
- 批准号:
10730660 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
2023 Lactic Acid Bacteria Biology, Symbioses and Applications GRC
2023年乳酸菌生物学、共生体和应用GRC
- 批准号:
10683583 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Metagenomic discovery and optimization of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris
针对痤疮皮肤杆菌治疗寻常痤疮的新型内溶素的宏基因组发现和优化
- 批准号:
10821291 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Development of Engineered Native Bacteria as a Tool for Functional Manipulation of the Gut Microbiome
开发工程原生细菌作为肠道微生物组功能操纵的工具
- 批准号:
10737475 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Chronic Murine Cerebral Mycosis: Pathogenesis, Neuroimmune Response, and Relevance to Alzheimer's Disease
慢性鼠脑真菌病:发病机制、神经免疫反应以及与阿尔茨海默病的相关性
- 批准号:
10723848 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Molecular mechanisms behind microbiota regulation of host amino acid and glucose homeostasis
微生物群调节宿主氨基酸和葡萄糖稳态背后的分子机制
- 批准号:
10639042 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
一种用于治疗多发性硬化症的新型免疫导向合成生物学药物
- 批准号:
10693465 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Development of a Gene-Transfer-Resistant and Biocontained Next-Generation Bacterial Host for Controlled Drug Delivery
开发用于受控药物输送的抗基因转移和生物包容的下一代细菌宿主
- 批准号:
10784171 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
3D Printed Engineered Living Materials for Drug Delivery
用于药物输送的 3D 打印工程活性材料
- 批准号:
10370976 - 财政年份:2022
- 资助金额:
$ 2.91万 - 项目类别: